Drug Trial Radar · NCT04275492
Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets
Last checked: Nov 19, 2026Latest source record: Mar 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
30
Actual
Start
Jul 24, 2020
Primary completion
Oct 1, 2020
Study completion Dec 1, 2020
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hongguan biological pharmaceutical co.
- First posted
- Feb 19, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of In two kinds of fasting and postprandial Chinese healthy subjects with Boehringer represent Ingelheim company production of hydrochloric acid Pramipexole zyban (specification: 0.26 mg/piece, in Pramipexole, commodity name: Siforl ®) as the reference preparation, study a single oral dose of macro crown biological pharmaceutical co., LTD. Production of Pramipexole Dihydrochloride Sustained Release Tablets (specification:The pharmacokinetic parameters of the drug were calculated after the time course of the drug in vivo (0.375mg/ tablet, as measured by pramipexole hydrochloride), and the human relative bioavailability of the two preparations were compared to evaluate their bioequivalence. A secondary purpose To evaluate the safety of fasting and postprandial oral test preparations and reference preparations.
Conditions
- Parkinson's Disease
Interventions
Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)Drug
Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)Drug
Siforl® is produced by Boehringer Ingelheim International Gmbh
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: [time range: 72 hours post-dose on Day 1,8]
- TmaxTime frame: [time range: 72 hours post-dose on Day 1,8]
- AUC(0-inf)Time frame: [time range: 72 hours post-dose on Day 1,8]
- AUC(0-72h)Time frame: [time range: 72 hours post-dose on Day 1,8]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital,ZheJiang Univercity
Hanzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.